SCHEMBL4368377

SCHEMBL4368377

O=C(NC(Cc1ccc(OC(F)(F)F)cc1)C(=O)O)c1ccc(Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.57
FPR2 P25090 1/20 0.54
PTPN1 P18031 3/20 0.53
GPR132 Q9UNW8 2/20 0.52
PPARG P37231 3/20 0.51
PPARA Q07869 3/20 0.51
EPHX2 P34913 1/20 0.51
KLKB1 P03952 1/20 0.49
USP30 Q70CQ3 1/20 0.47
ITGB1 P05556 1/20 0.47
ITGA4 P13612 1/20 0.47
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
GCGR P47871 2/20 0.46
GIPR P48546 2/20 0.46
TRPV1 Q8NER1 1/20 0.46
MAPK14 Q16539 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4364518 0.90 FPR2 (0.55) CA2FPR2PTPN1GPR132PPARG
SCHEMBL4364758 0.90 CA2 (0.58) CA2FPR2PTPN1GPR132PPARG
SCHEMBL4364527 0.89 CA2 (0.63) CA2FPR2PTPN1GPR132PPARG
SCHEMBL5926412 0.87 FPR2 (0.52) CA2FPR2PTPN1GPR132PPARG
SCHEMBL21931656 0.86 CA2 (0.62) CA2FPR2PTPN1GPR132PPARG
SCHEMBL4374566 0.86 KLKB1 (0.51) PPARGPPARAEPHX2KLKB1USP30
SCHEMBL28776570 0.86 KLKB1 (0.55) CA2PPARGPPARAEPHX2KLKB1
SCHEMBL3995770 0.85 FPR2 (0.63) CA2FPR2PTPN1GPR132PPARG
SCHEMBL5926235 0.83 FPR2 (0.55) CA2FPR2PTPN1GPR132PPARG
SCHEMBL5926737 0.83 FPR2 (0.55) CA2FPR2PTPN1GPR132PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908466-B1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO CO LTD (JP) 2014-02-19 EP disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
CN-101267813-A Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO CO LTD (JP) 2008-09-17 CN disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 CA2 364/4885FPR2 3587/4885PTPN1 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.